A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A (NCT05911763)
Prospective, Observational , Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients With Hemophilia A
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating physician independently from the decision to include patients in the study. No study medication is provided. The data related to efanesoctocog alfa effectiveness, safety and usage will be collected prospectively during routine visits (expected annual/semi-annual visits) for up to 5 years following enrollment /treatment initiation.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center- Site Number : 8400008 — Gilbert, Arizona
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Banner MD Anderson Cancer Center- Site Number : 8400008 — Gilbert, Arizona
- Loma Linda University- Site Number : 8400015 — Loma Linda, California
- Orthopedic Institute for Children- Site Number : 8400004 — Los Angeles, California
- The Center for Inherited Blood Disorders- Site Number : 8400001 — Orange, California
- University of Colorado Hemophilia and Thrombosis Center- Site Number : 8400019 — Aurora, Colorado
- William A. Shands Hospital at the University of Florida- Site Number : 8400032 — Gainesville, Florida
- Johns Hopkins All Childrens Hospital - Outpatient Care Center - PIN- Site Number : 8400025 — St. Petersburg, Florida
- Rush University Medical Center -1725 W Harrison St- Site Number : 8400014 — Chicago, Illinois
- The Bleeding and Clotting Disorders Institute- Site Number : 8400005 — Peoria, Illinois
- Indiana Hemophilia and Thrombosis Center- Site Number : 8400013 — Indianapolis, Indiana
- University Of Iowa Hospitals And Clinics- Site Number : 8400026 — Iowa City, Iowa
- ~Massachusetts General Hospital- Site Number : 8400017 — Boston, Massachusetts
- Dana Farber and Boston Children's Hospital- Site Number : 8400031 — Boston, Massachusetts
- University of Michigan Hospital - 1500 E Medical Center Dr- Site Number : 8400023 — Ann Arbor, Michigan
- M Health Fairview- Masonic Cancer Clinic - Clinics- Site Number : 8400010 — Minneapolis, Minnesota
- Mayo Clinic - PPDS- Site Number : 8400035 — Rochester, Minnesota
- Mississippi Center For Advanced Medicine - 7731 Old Canton Rd- Site Number : 8400016 — Madison, Mississippi
- University of Nebraska Medical Center - 985400 Nebraska Medical Center- Site Number : 8400009 — Omaha, Nebraska
- Children's Specialty Center - Las Vegas- Site Number : 8400007 — Las Vegas, Nevada
- Weill Cornell Medicine-New York Presbyterian Hospital- Site Number : 8400021 — New York, New York
- Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400006 — Cincinnati, Ohio
- Hemophilia Center of Western Pennsylvania- Site Number : 8400012 — Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center- Site Number : 8400003 — Nashville, Tennessee
- University of Texas Southwestern Medical Center-2001 Inwood Rd- Site Number : 8400020 — Dallas, Texas
- University of Texas Southwestern Medical Center- Site Number : 8400011 — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hemophilia A
- Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" — Little Rock, Arkansas
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Los Angeles, California
- Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A — Milwaukee, Wisconsin
- A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Gainesville, Florida
- Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults — Mountain View, California
Explore by condition: All Hemophilia A clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.